STOCK TITAN

Certara Inc - CERT STOCK NEWS

Welcome to our dedicated news page for Certara (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Certara's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Certara's position in the market.

Rhea-AI Summary
Certara, Inc. launches Certara Cloud, a platform integrating its scientific software solutions for model-informed drug development. The platform aims to enhance customer experience, streamline workflows, and provide real-time collaboration and security benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary
Certara, Inc. (CERT) will release Q1 2024 financial results on May 7th, 2024, followed by a conference call at 5:00PM ET. The company will also participate in the BofA Securities Healthcare Conference on May 14th. Live and archived webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences earnings
-
Rhea-AI Summary
Certara, Inc. provides full-year 2024 financial guidance, reporting $88.0 million in revenue for the fourth quarter of fiscal year 2023, a 2% increase over the previous year. The net loss was $12.5 million due to increased operating expenses and fair value adjustments. The company aims to grow in 2024 with investments in new software products and artificial intelligence capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
Rhea-AI Summary
Certara, Inc. (CERT) will release its financial results for Q4 and full year 2023 on February 29th, 2024. The company will also participate in the Barclays 26th Annual Global Healthcare Conference on March 13th. Live and archived webcasts will be available on the Certara website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences earnings
-
Rhea-AI Summary
Certara, Inc. (Nasdaq: CERT) has acquired Applied BioMath, establishing the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence. This acquisition aims to contribute to faster and more effective medicine development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
-
Rhea-AI Summary
Certara, Inc. (CERT) introduces Simcyp™ Biopharmaceutics software, aiding drug developers in formulating complex novel and generic small molecule medicines quickly and cost-effectively. The software replaces costly clinical bioequivalence studies, optimizes formulations for complex drugs, and delivers value across critical areas to achieve formulation success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
none
Rhea-AI Summary
CERT - Certara, Inc. (Nasdaq: CERT) reports 1% revenue growth in Q3 2023, with $85.6 million revenue and $49.0 million net loss. The company reiterates full year 2023 financial guidance with revenue expected in the range of $345 million to $360 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
-
Rhea-AI Summary
Certara, Inc. to release Q3 2023 financial results and participate in Stephens Annual Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
conferences earnings
-
Rhea-AI Summary
Certara, Inc. successfully supports 300 completed submissions to regulatory agencies worldwide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
Rhea-AI Summary
Certara, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
conferences
Certara Inc

Nasdaq:CERT

CERT Rankings

CERT Stock Data

2.83B
109.07M
2.92%
97.79%
3.55%
Software Publishers
Information
Link
United States
Princeton

About CERT

certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.